Lysine Mimetic Compounds for Antiarrhythmic Peptide Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antiarrhythmic peptides exhibit low stability, short half-life, and limited oral bioavailability, making them ineffective for sustained pharmacological activity, particularly in treating heart-related conditions associated with impaired gap junction intercellular communication.
Innovation Solution
Development of lysine mimetic compounds with specific structural formulas (Formulas II and III) that enhance bioavailability and stability, allowing for effective antiarrhythmic activity and broader therapeutic applications, including cardiovascular diseases and other conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiarrhythmic peptides are used to treat heart disease, then gap junction intercellular communication is facilitated, but stability and half-life are insufficient
Solution Approach 1:
The patent modifies the chemical structure of antiarrhythmic peptides by introducing specific amino acid substitutions and structural modifications. These parameter changes in molecular composition transform the peptides into orally bioavailable compounds with enhanced stability while preserving their ability to facilitate gap junction communication and treat arrhythmias.
2Reliability
If antiarrhythmic peptides are administered, then antiarrhythmic effect is achieved, but oral bioavailability is limited
Solution Approach 1:
The patent applies parameter changes by modifying molecular weight, hydrophobicity, and structural conformation of the peptides. These modifications enable the compounds to withstand gastrointestinal degradation and achieve sufficient oral bioavailability while maintaining antiarrhythmic efficacy through preserved gap junction facilitating activity.
3Reliability
If peptides are used for gap junction communication, then cellular coupling is enhanced, but half-life is short
Solution Approach 1:
The patent extends half-life through parameter changes including resistance to proteolytic degradation and optimized pharmacokinetic properties. The modified compounds maintain prolonged circulation and tissue persistence while preserving their ability to enhance gap junction communication between cardiomyocytes.
4Reliability
If structural modifications are made to improve bioavailability, then pharmacological activity is enhanced, but molecular complexity increases
Solution Approach 1:
The patent applies local quality by introducing specific modifications at particular positions within the peptide sequence rather than global structural changes. This targeted approach enhances bioavailability and stability through localized amino acid substitutions while maintaining the overall simplicity and recognizability of the parent peptide structure.
Data Source
Figure 1
AI summary
Lysine mimetic compounds having useful pharmacological activity such as antiarrhythmic activity and desirable bioavailability properties are disclosed